|1.||Non-Hodgkin Lymphoma (Lymphosarcoma)
|3.||B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
|4.||Hairy Cell Leukemia
|1.||Byrd, John C: 123 articles (12/2015 - 02/2002)|
|2.||Keating, Michael J: 102 articles (11/2015 - 02/2002)|
|3.||Kipps, Thomas J: 87 articles (12/2015 - 03/2002)|
|4.||O'Brien, Susan: 76 articles (06/2015 - 02/2002)|
|5.||Robak, Tadeusz: 74 articles (12/2015 - 01/2002)|
|6.||Stilgenbauer, Stephan: 66 articles (12/2015 - 08/2002)|
|7.||Wierda, William G: 63 articles (11/2015 - 06/2003)|
|8.||Hallek, Michael: 62 articles (11/2015 - 01/2002)|
|9.||Ferrajoli, Alessandra: 52 articles (11/2015 - 08/2002)|
|10.||Kay, Neil E: 52 articles (09/2015 - 10/2002)|
01/01/2003 - "Fludarabine combined with cyclophosphamid is highly effective in the treatment of chronic lymphocytic leukemia."
10/08/1992 - "Patients with untreated B-cell chronic lymphocytic leukemia have a high rate of complete remission when given the halogenated nucleoside analogue fludarabine. "
01/01/2012 - "Fludarabine-based therapy is widely approved as a first-line treatment for chronic lymphocytic leukemia (CLL). "
03/01/2010 - "R-DHAP is effective in fludarabine-refractory chronic lymphocytic leukemia."
07/01/2002 - "Fludarabine is a renally excreted agent that is an effective treatment for chronic lymphocytic leukemia (CLL), a disease predominantly of the elderly. "
|2.||rituximab (Mabthera)FDA Link
08/01/2013 - "In conclusion, rituximab is cleared so rapidly during the initial cycles of therapy for chronic lymphocytic leukemia that most patients have only transient serum levels. "
08/01/2013 - "Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia."
03/01/2004 - "Initiation of rituximab infusion in chronic lymphocytic leukemia patients leads to rapid clearance of CD20(+) cells. "
06/01/2000 - "We report on two patients with chemoresistant B-cell chronic lymphocytic leukemia who were treated successfully with the monoclonal anti-CD 20 antibody rituximab. "
05/01/2013 - "In chronic lymphocytic leukemia (CLL), response rates to single-agent rituximab at the NHL dose were low, but the use of higher doses or more frequent dosing have led to improved response rates, suggesting that a higher dose may be required. "
|3.||alemtuzumab (Campath)FDA Link
03/01/2012 - "Alemtuzumab has been shown to be effective in poor-prognosis chronic lymphocytic leukemia (CLL); treatment, however, has been associated with significant toxicity. "
06/01/2007 - "With respect to outcomes such as survival, response rate, response duration, time to progression, and quality of life, is alemtuzumab a beneficial treatment option for patients with B-cell chronic lymphocytic leukemia (cll)?What toxicities are associated with the use of alemtuzumab?Which"
01/15/2005 - "The anti-CD52 antibody alemtuzumab is effective in the treatment of patients with chronic lymphocytic leukemia (CLL). "
03/15/2004 - "Alemtuzumab therapy is effective for some refractory chronic lymphocytic leukemia (CLL), but identifying responders requires at least 8 weeks of therapy. "
02/01/2004 - "Campath-1H is known as an effective treatment of chronic lymphocytic leukemia (CLL). "
|4.||Cyclophosphamide (Cytoxan)FDA LinkGeneric
02/01/1989 - "A 55-year-old male with chronic lymphocytic leukemia developed a skin eruption after receiving oral cyclophosphamide. "
03/01/1970 - "Cyclophosphamide-induced changes in circulating lymphocyte kinetics in chronic lymphocytic leukemia."
01/01/2003 - "To determine its antitumor activity in combination with cyclophosphamide, we initiated a Phase II trial of the two agents in patients with advanced chronic lymphocytic leukemia (CLL) or prolymphocytic leukemia (PLL). "
02/01/1989 - "Cutaneous vasculitis due to cyclophosphamide therapy for chronic lymphocytic leukemia."
01/01/1983 - "We report a case of transitional cell carcinoma of the bladder after cyclophosphamide therapy for chronic lymphocytic leukemia. "
|5.||Chlorambucil (Leukeran)FDA Link
01/01/1980 - "Forty patients with lymphocytic lymphoma were treated with escalating doses of chlorambucil biweekly starting at a dose of 0.4 mg/kg. Fifty percent of patients achieved a complete remission, usually after 6-12 months of therapy. "
02/01/2009 - "The overall remission rate was 59% in a prospective, randomized study of untreated patients with chronic lymphocytic leukemia, which was significantly greater than the rate of 26% in the chlorambucil control arm (P < 0.001). "
12/17/2015 - "Ibrutinib was superior to chlorambucil in previously untreated patients with CLL or small lymphocytic lymphoma, as assessed by progression-free survival, overall survival, response rate, and improvement in hematologic variables. "
09/01/2015 - "Its superiority in association with chlorambucil as compared with chlorambucil alone has led to its approval as a first-line treatment for chronic lymphocytic leukemia, for patients who are not candidates for a more intensive treatment. "
06/01/2014 - "Obinutuzumab is a novel therapeutic anti-CD20 monoclonal antibody recently approved by the United States Food and Drug Administration (FDA) for use in combination with chlorambucil as first-line treatment of chronic lymphocytic leukemia (CLL). "
04/01/1993 - "High complete remission rate from 2-chloro-2'-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count."
11/15/2000 - "In this study it is shown, by means of several assays on whole cells and isolated mitochondria, that 2-chloro-2'-deoxyadenosine (2CdA) and 2-choloro-2'-ara-fluorodeoxyadenosine (CaFdA) disrupt the integrity of mitochondria from primary chronic lymphocytic leukemia (B-CLL) cells. "
06/01/1999 - "The aim of our study was to determine the efficacy and toxicity of 2-chlorodeoxyadenosine (2-CdA) in 2-hour infusions in the treatment of elderly patients with B-cell chronic lymphocytic leukemia (B-CLL). "
04/01/1999 - "The aim of the study was to determine the effectiveness of 2-chlorodeoxyadenosine (2-CdA) administered in 2-h i.v. infusions in the treatment of B cell chronic lymphocytic leukemia (B-CLL) in patients 55 years old and younger. "
01/01/1996 - "Current results and prospective trials of cladribine in chronic lymphocytic leukemia."
07/01/2003 - "Therapeutic results in advanced chronic lymphocytic leukemia (CLL) are still unsatisfactory in terms of complete remission achievement and duration, in spite of the extensive use of purine analogs. "
03/01/2012 - "Therefore, individual patient data were sought for all randomized trials in untreated chronic lymphocytic leukemia which involved a purine analog, but which did not include antibody therapies. "
03/01/2012 - "Systematic review of purine analog treatment for chronic lymphocytic leukemia: lessons for future trials."
02/10/2015 - "B-chronic lymphocytic leukemia (B-CLL) patients harboring p53 mutations are invariably refractory to therapies based on purine analogues and have limited treatment options and poor survival. "
03/01/2012 - "Deletion of ATM detected by fluorescent in situ hybridization (FISH) in chronic lymphocytic leukemia predicts short treatment free survival and poor outcome following alkylator/purine analogue therapy. "
11/01/2013 - "Bendamustine proved to be effective for the treatment of chronic lymphocytic leukemia (CLL). "
11/01/2009 - "Bendamustine: a new treatment option for chronic lymphocytic leukemia."
10/01/2005 - "Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group."
09/01/2015 - "Routine Use of Bendamustine in Patients with Chronic Lymphocytic Leukemia: An Observational Study."
01/01/2001 - "In an open phase-II study we treated 23 patients with a median age of 62 years at study entry (43-86 years) with advanced, refractory or relapsed (Rai stage III n = 9, Rai stage IV n = 14) chronic lymphocytic leukemia (CLL) with bendamustine. "
02/01/1988 - "The chronic lymphocytic leukemias are diseases of both clinical and morphological diversity and the application of monoclonal antibodies can prove helpful in their classification. "
01/01/1984 - "T-cell subsets were determined by the Leu monoclonal antibodies in the peripheral blood and/or bone marrow of 52 patients with B-cell chronic lymphocytic leukemia (B-CLL) not on therapy at the time of study. "
12/01/2015 - "Treatment of chronic lymphocytic leukemia with monoclonal antibodies, where are we heading?"
09/01/2015 - "Over the last few years, several new immunological drugs, particularly monoclonal antibodies (mAbs), immunomodulatory drugs and B-cell receptor (BCR) pathway inhibitors have been developed and investigated in chronic lymphocytic leukemia (CLL). "
06/25/2015 - "Current treatment strategies for chronic lymphocytic leukemia (CLL) involve a combination of conventional chemotherapeutics, monoclonal antibodies, and targeted signaling inhibitors. "
|10.||lenalidomide (CC 5013)FDA Link
01/01/2010 - "Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics."
04/01/2013 - "Lenalidomide is effective against relapsed chronic lymphocytic leukemia (CLL). "
12/01/2006 - "Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study."
04/01/2013 - "Long-term molecular remission with lenalidomide treatment of relapsed chronic lymphocytic leukemia."
05/16/2013 - "In vitro studies have demonstrated that lenalidomide repairs the T-cell immunologic synapse defect in chronic lymphocytic leukemia (CLL). "
|1.||Drug Therapy (Chemotherapy)
08/01/2004 - "Novel therapeutic approaches with conventional chemotherapy and monoclonal antibody combinations have improved the complete remission rates in chronic lymphocytic leukemia. "
08/08/2002 - "Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy."
06/01/1989 - "A case of prolymphocytic transformation of chronic lymphocytic leukemia (CLL) is presented in which complete peripheral morphometric remission and lengthy survival were observed after intensive chemotherapy. "
05/15/1989 - "This study evaluates residual disease in 28 B-cell chronic lymphocytic leukemia (B-CLL) patients who obtained a clinicohematologic remission after intensive chemotherapy. "
01/01/2000 - "B cell chronic lymphocytic leukemia (B-CLL) cannot be cured with conventional chemotherapy. "
10/01/2014 - "Abnormalities in ATM and TP53 genes represent important predictive factors in chronic lymphocytic leukemia (CLL); however, the efficacy of CD20 targeting immunotherapy is only poorly defined in the affected patients. "
11/01/2011 - "Chronic lymphocytic leukemia (CLL) therapy has evolved over the past few decades as modern chemo-immunotherapy significantly improved the response and survival of CLL patients. "
05/01/2014 - "Immunotherapy using mAbs is a safe and effective method for the treatment of chronic lymphocytic leukemia (CLL) and other lymphoid malignancies. "
06/15/2012 - "Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule."
10/01/2010 - "Definition of a target for immunotherapy and results of the first Peptide vaccination study in chronic lymphocytic leukemia."
11/01/2005 - "To evaluate the efficacy of reduced intensity conditioning (RIC) allogeneic transplant in 30 patients with poor-prognosis chronic lymphocytic leukemia (CLL) and/or high-risk molecular/cytogenetic characteristics. "
07/15/2009 - "Allogeneic nonmyeloablative hematopoietic stem cell transplant (NM-HSCT) can result in durable remission of chronic lymphocytic leukemia (CLL). "
01/01/1977 - "Studies on the local graft versus host reactivity of normal and chronic lymphocytic leukemia lymphocytes. "
06/01/2015 - "With the growing complexity of treatment options for chronic lymphocytic leukemia (CLL) and variables that influence the underlying biology of this disease, providing allogeneic stem cell transplant (alloSCT) to appropriate candidates poses a challenge for transplant physicians. "
03/01/2015 - "Allogeneic stem cell transplant (alloSCT) can overcome the adverse prognosis of chronic lymphocytic leukemia with 17p deletion (17p- CLL). "
|4.||Stem Cell Transplantation
05/10/2015 - "Allogeneic stem-cell transplantation (SCT) induces long-term remission in a fraction of patients with high-risk chronic lymphocytic leukemia (CLL) or Richter's transformation (RT). "
05/01/2003 - "Allogeneic stem cell transplantation (SCT) using reduced-intensity conditioning (RIC) has potential to be a promising treatment of aggressive chronic lymphocytic leukemia (CLL). "
06/09/2011 - "Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLC."
10/01/2006 - "Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia."
05/24/2012 - "The CLL3 trial was designed to study intensive treatment including autologous stem cell transplantation (autoSCT) as part of first-line therapy in patients with chronic lymphocytic leukemia (CLL). "
|5.||Combination Drug Therapy (Combination Chemotherapy)
01/01/2015 - "Targeted therapy with combination chemotherapy and monoclonal antibody in patients with chronic lymphocytic leukemia represents a significant advance in the treatment of this disease."
06/01/1984 - "Forty patients with diffuse poorly differentiated lymphocytic lymphoma (DPDL) Stages II-IV were treated with three different and successive combination chemotherapy protocols. "
10/01/1982 - "Combination chemotherapy ("MABOP") in advanced refractory lymphocytic lymphoma with unfavorable histology."
10/01/1974 - "Combination chemotherapy of advanced lymphocytic lymphoma. "
06/01/1962 - "Combination chemotherapy in chronic lymphocytic leukemia."